modelEflornithine
Extends from Pharmacolibrary.Drugs.ATC.L.L01XX79.
Information
| name: | Eflornithine | |
| ATC code: | L01XX79 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 400 | mg |
| volume of distribution: | 0.25 | L |
| clearance: | 350 | ml/min |
| other parameters in model implementation | ||
Eflornithine is an irreversible inhibitor of ornithine decarboxylase, used in the treatment of African trypanosomiasis (sleeping sickness) due to Trypanosoma brucei gambiense. It was also formerly used topically for the reduction of unwanted facial hair. Eflornithine is generally administered intravenously for the treatment of sleeping sickness and is not widely approved or used for other major indications today.
Pharmacokinetics
Pharmacokinetic parameters estimated from published data for adult patients with late-stage African trypanosomiasis treated with intravenous eflornithine.
References
Amilon, C, et al., & Jansson-Löfmark, R (2022). Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy. The AAPS journal 24(3) 48–None. DOI:10.1208/s12248-022-00693-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35338410
Johansson, CC, et al., & Jansson-Löfmark, R (2013). Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat. Journal of pharmacokinetics and pharmacodynamics 40(1) 117–128. DOI:10.1007/s10928-012-9293-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/23307171
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)